Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies



Rating:

Share or cite this content

Citations should be made in the following way:
A. Morell (Hradec Králové, Czech Republic), J. Milara (Valencia, Spain), L. Laštovicková (Hradec Králové, Czech Republic), I. Roger (Valencia, Spain), A. García-Lliberós (Valencia, Spain), E. Zapater-Latorre (Valencia, Spain), M. Armengot (Valencia, Spain), J. Cortijo (Valencia, Spain), V. Wsól (Hradec Králové, Czech Republic). Late Breaking Abstract - Aldo-keto reductases expression correlate corticoids efficacy in vitro and on chronic rhinosinusitis with nasal polyps. 891

Member's Comments

No comment yet.

Related content which might interest you: MUC4 overexpression correlates corticoid resistance in chronic rhinosinusitis with nasal polyps Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 Late Breaking Abstract - Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 IL-19 as putative biomarker for chronic rhinosinusitis with nasal polyps Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010 Mucin 1 downregulation associates with corticoid resistance in chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Increased expression of IL-19 in metaplastic epithelium of patients with chronic rhinosinusitis and nasal polyps Source: Annual Congress 2011 - Epithelial cell biology Year: 2011 Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Late Breaking Abstract - Systemic IL-26 correlates with improved asthma control in children with allergic sensitization Source: International Congress 2018 – Molecular and cellular determinants of the developing lung Year: 2018 Late Breaking Abstract - Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020 Late Breaking Abstract - A GATA3-specific DNAzyme attenuates sputum eosinophilia in COPD patients with eosinophilic airway inflammation Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Role of non cholinergic system components in chronic rhinosinusitis and nasal polyps Source: Annual Congress 2010 - Novel cellular mechanisms in lung disease Year: 2010 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019